Challenging production of Auger electron emitter platinum-195m via double-neutron capture activation of an iridium-193 target

• Autorzy: Wawrowicz Kamil , Bilewicz Aleksander

Identyfikatory

DOI

10.5604/01.3001.0054.1821

• Języki publikacji: EN

Abstrakty

EN

Targeted Auger electron (AE) therapy exhibits great potency against small tumors and metastatic sites, which to date have no effective therapeutic options. However, the development of AE-based therapy is significantly limited due to the low availability of the most promising radionuclides, being the consequence of the poor cognition of relevant nuclear pathways and insufficient accessibility of highly enriched target materials and specific infrastructure. Therefore, the development and investigation approaches to overcome this limitation are highly complex and challenging. In the present paper, as a second group worldwide, we perform experimental evaluation of double-neutron capture of a 195mPt production - radionuclide showing the most favourable characteristics for targeted Auger electron therapy. For this purpose we investigated two-step iridium target activation via 193Ir(n,γ) 194Ir(n,γ) 195mIr(β-)→195mPt. In presenting the current state of knowledge of identified production methods of this radionuclide, we highlight the limitations and challenges of cyclotron- and reactor-based approaches. With theoretical calculations followed by short-time irradiation with thermal neutron flux, we describe numerous nuclear and chemical difficulties associated with an investigated nuclear pathway. Obtained results reveal that research and commercial application of this method is significantly hindered or even impossible at the current state of knowledge. We point out the most critical limitations which need to be addressed for further consideration of the mentioned strategy. Therefore, 195mPt application for targeted Auger therapy still remains challenging and requires efforts to overcome the limitations.

Słowa kluczowe

EN

platinum-195m; platinum-193m; Auger electron therapy; double-neutron capture; iridium-193

• Wydawca: Uniwersytet Jagielloński - Collegium Medicum ; Index Copernicus Sp. z o.o.
• Czasopismo: Bio-Algorithms and Med-Systems
• Rocznik: 2023
• Tom: Vol. 19, no. 1
• Strony: 35--39
• Opis fizyczny: Bibliogr. 11 poz., rys., tab.

Twórcy

autor

Wawrowicz Kamil

• Institute of Nuclear Chemistry and Technology, Warsaw, Poland

• https://orcid.org/0000-0003-3818-5840

autor

Bilewicz Aleksander

• Institute of Nuclear Chemistry and Technology, Warsaw, Poland

• https://orcid.org/0000-0003-2490-3303

Bibliografia

• 1. Aghevlian S, Boyle AJ, Reilly RM. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons. Adv Drug Deliv Rev. 2017;109:102-18. doi: 10.1016/j.addr.2015.12.003.
• 2. Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol. 2001;40(5): 602-8. doi: 10.1080/028418601750444141.
• 3. Wawrowicz K, Majkowska-Pilip A, Gaweł D, Chajduk E, Pieńkowski T, Bilewicz A. Au@Pt Core-Shell Nanoparticle Bioconjugates for the Therapy of HER2+ Breast Cancer and Hepatocellular Carcinoma. Model Studies on the Applicability of 193mPt and 195mPt Radionuclides in Auger Electron Therapy. Molecules 2021;26:2051. doi: doi.org/10.3390/molecules26072051.
• 4. Wawrowicz K, Żelechowska-Matysiak K, Majkowska-Pilip A, Wierzbicki M, Bilewicz A. Platinum nanoparticles labelled with iodine-125 for combined „chemo-Auger electron” therapy of hepatocellular carcinoma. Nanoscale Adv. 2023;5(12):3293-3303. doi: 10.1039/d3na00165b.
• 5. Hilgers K, Coenen HH, Qaim SM. Production of the therapeutic radionuclides 193mPt and 195mPt with high specific activity via alpha-particle-induced reactions on 192Os. Appl Radiat Isot. 2008;66(4):545-51. doi: 10.1016/j.apradiso.2007.10.009.
• 6. Toth G. A Novel Target for Reactor-produced 193mPt. Appl Radiat Isot. 1980;31(7):411-3.
• 7. Zeevaart JR, Wagener J, Marjanovic-Painter B, Sathekge M, Soni N, Zinn C, et al.: Production of high specific activity (195m) Pt-cisplatinum at South African Nuclear Energy Corporation for Phase 0 clinical trials in healthy individual subjects. J Labelled Comp Radiopharm. 2013;56(9-10):495-503. doi: 10.1002/jlcr.3091.
• 8. Knapp R, Mirzadeh S, Beets AL, Du M. Production of Therapeutic Radioisotopes in the ORNL High Flux Isotope Reactor (HFIR) for Applications in Nuclear Medicine, Oncology and Interventional Cardiology. J Radioanal Nucl Chem. 2005;263: 503-9. doi: 10.1007/s10967-005-0083-4.
• 9. Bonardi M, Birattari C, Gallorini M, Arginelli D. Cyclotron production, radiochemical separation and quality control of platinum radiotracers for toxicological studies. J Radioanal Nucl Chem. 1998;236:159-64. doi: doi.org/10.1007/BF02386335.
• 10. Uddin MS, Scholten B, Hermanne A, Sudár S, Coenen HH, Qaim SM. Radiochemical determination of cross sections of alpha-particle induced reactions on 192Os for the production of the therapeutic radionuclide 193mPt. Appl Radiat Isot. 2010;68(10):2001-6. doi: 10.1016/j. apradiso.2010.05.002.
• 11. Valkema R, de Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In111-DTPA] octreotide: The Rotterdam experience. Semin. Nucl. Med. 2002;32:110-22.

Uwagi

Opracowanie rekordu ze środków MEiN, umowa nr SONP/SP/546092/2022 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2022-2023).